Forte Biosciences (FBRX) Profit After Tax Growth (3y) (2019 - 2026)
Forte Biosciences (FBRX) Profit After Tax Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 9.53% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -27.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 70.25% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Forte Biosciences | 1.37 Bn | 1.31 Bn | - | -48.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.55% |
| Dec 31, 2025 | -71.90% |
| Sep 30, 2025 | -73.25% |
| Jun 30, 2025 | -54.76% |
| Mar 31, 2025 | -82.71% |
| Dec 31, 2024 | -28.88% |
| Sep 30, 2024 | -2.68% |
| Jun 30, 2024 | -29.12% |
| Mar 31, 2024 | -15.59% |
| Dec 31, 2023 | -8.67% |
| Sep 30, 2023 | -25.00% |
| Jun 30, 2023 | 36.51% |
| Mar 31, 2023 | -48.79% |
| Dec 31, 2022 | 22.76% |
| Sep 30, 2022 | -70.17% |
| Jun 30, 2022 | -68.89% |
| Mar 31, 2022 | -29.39% |
| Dec 31, 2021 | 44.56% |
| Sep 30, 2021 | -172.51% |
| Jun 30, 2021 | 28.78% |